Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.25)
# 398
Out of 4,884 analysts
231
Total ratings
41.04%
Success rate
20.29%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLDB Solid Biosciences | Assumes: Overweight | $16 | $5.03 | +218.09% | 1 | May 22, 2025 | |
| FULC Fulcrum Therapeutics | Upgrades: Overweight | $10 | $6.92 | +44.51% | 4 | May 15, 2025 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $30 | $10.25 | +192.68% | 6 | May 14, 2025 | |
| ZVRA Zevra Therapeutics | Reiterates: Overweight | $25 | $9.74 | +156.67% | 2 | May 14, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $113 → $112 | $49.07 | +128.25% | 19 | May 7, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $20 → $23 | $18.93 | +21.50% | 7 | May 7, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $163 → $81 | $18.24 | +344.08% | 16 | May 7, 2025 | |
| TSHA Taysha Gene Therapies | Reiterates: Overweight | $7 | $2.45 | +185.71% | 16 | Apr 28, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Overweight | $67 → $123 | $86.65 | +41.95% | 6 | Mar 27, 2025 | |
| XFOR X4 Pharmaceuticals | Reiterates: Overweight | $90 | $1.89 | +4,661.90% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $2.87 | +143.90% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $99 → $132 | $54.75 | +141.10% | 8 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $18.28 | +36.76% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $118 | $39.91 | +195.67% | 18 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $36 | $31.98 | +12.57% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $22.00 | +204.55% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $6.10 | +244.26% | 7 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $29 | $10.16 | +185.43% | 13 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $3.72 | +356.99% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $1.17 | +583.76% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $58 | $14.42 | +302.22% | 9 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $2.77 | +297.11% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $5.89 | +205.60% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $4.61 | +203.69% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $2.28 | +470.18% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.44 | +1,358.33% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.01 | +494.06% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $1.78 | +1,023.60% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $3.17 | +625.55% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $1.19 | +75,530.25% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $41 | $0.67 | +6,049.69% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $3.54 | +11,199.44% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $0.74 | +11,370.99% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $7.36 | +2,345.65% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $1.16 | +3,779.31% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $0.96 | +1,049.43% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.60 | +3,650.00% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.34 | +6,616.42% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $1.83 | +137,982.19% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $160 | $0.44 | +36,263.64% | 1 | Jan 9, 2020 |
Solid Biosciences
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $5.03
Upside: +218.09%
Fulcrum Therapeutics
May 15, 2025
Upgrades: Overweight
Price Target: $10
Current: $6.92
Upside: +44.51%
Capricor Therapeutics
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $10.25
Upside: +192.68%
Zevra Therapeutics
May 14, 2025
Reiterates: Overweight
Price Target: $25
Current: $9.74
Upside: +156.67%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $113 → $112
Current: $49.07
Upside: +128.25%
Rigel Pharmaceuticals
May 7, 2025
Maintains: Neutral
Price Target: $20 → $23
Current: $18.93
Upside: +21.50%
Sarepta Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $18.24
Upside: +344.08%
Taysha Gene Therapies
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $2.45
Upside: +185.71%
Soleno Therapeutics
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $86.65
Upside: +41.95%
X4 Pharmaceuticals
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $1.89
Upside: +4,661.90%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $2.87
Upside: +143.90%
Mar 18, 2025
Maintains: Overweight
Price Target: $99 → $132
Current: $54.75
Upside: +141.10%
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $18.28
Upside: +36.76%
Feb 26, 2025
Reiterates: Overweight
Price Target: $118
Current: $39.91
Upside: +195.67%
Feb 26, 2025
Reiterates: Neutral
Price Target: $36
Current: $31.98
Upside: +12.57%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $22.00
Upside: +204.55%
Jan 15, 2025
Reiterates: Overweight
Price Target: $21
Current: $6.10
Upside: +244.26%
Jan 2, 2025
Reiterates: Overweight
Price Target: $29
Current: $10.16
Upside: +185.43%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $3.72
Upside: +356.99%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $1.17
Upside: +583.76%
Dec 10, 2024
Maintains: Overweight
Price Target: $28 → $58
Current: $14.42
Upside: +302.22%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.77
Upside: +297.11%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $5.89
Upside: +205.60%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $4.61
Upside: +203.69%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $2.28
Upside: +470.18%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.44
Upside: +1,358.33%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.01
Upside: +494.06%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $1.78
Upside: +1,023.60%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $3.17
Upside: +625.55%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $1.19
Upside: +75,530.25%
Aug 10, 2023
Maintains: Overweight
Price Target: $44 → $41
Current: $0.67
Upside: +6,049.69%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $3.54
Upside: +11,199.44%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $0.74
Upside: +11,370.99%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $7.36
Upside: +2,345.65%
May 26, 2021
Initiates: Overweight
Price Target: $45
Current: $1.16
Upside: +3,779.31%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $0.96
Upside: +1,049.43%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.60
Upside: +3,650.00%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $1.34
Upside: +6,616.42%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $1.83
Upside: +137,982.19%
Jan 9, 2020
Initiates: Overweight
Price Target: $160
Current: $0.44
Upside: +36,263.64%